Clinical Practice of ABO Blood Group Molecular Analysis: Chinese Expert Consensus
Junhua Hu,Yushiang Lin,Rong Xiao,Shuang Zhao,Xiaoning Wang,Haolin Zhou,Jiangcun Yang,Zhiwei Liu,Ping Xu,Changjiu Tang,X. Y. Zhou,Maohong Bian,Haiyan Wang,Chan Zhang,Xiaojun Ma,Yujuan Xu,Yuanshuai Huang,Peiyuan Zhu,Bailing Zhang,Zhuning Mo,Wenting Wang,Daxi Ren,Qijun Fu,Min Zhang,Weixin Hu,Meng Li,Hongjun Yang,Qing Nian,Ziliang Ao,Peng Zhang,Lei Yu,J. F. Chang,Bing Sun,Jianping Gong
DOI: https://doi.org/10.46701/bg.2023022023023
2023-01-01
Blood and Genomics
Abstract:The ABO blood group, based on molecular biological detection technology, has the advantages of simple operation, high sensitivity, and standardized result interpretation, and is not affected by sample immunological characteristics. However, clinically, performance verification, clinical application scope, quality management, abnormal result processing, and other issues associated with the ABO blood group molecular detection technology are relatively complex, and there is a lack of unified norms and standards. Therefore, from the perspective of the whole process of ABO molecular biology detection, this study aims to provide standardized opinions on important links affecting the detection results, common problems encountered in the detection process, and the assessment and treatment of abnormal results. Finally, a Chinese expert consensus on molecular biological technology based on genotyping and sequencing detection was put forward, which standardizes the detection process, improves the accuracy of results, and promotes the development of technology and broader clinical application.